622 results on '"Fijnvandraat, K."'
Search Results
2. A high rate of post thrombotic complication in pediatric portal vein thrombosis
3. In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients
4. Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders
5. The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development
6. Use of the oxygen gradient ektacytometry in the dose titration of hydroxyurea therapy in children with sickle cell disease.
7. A Generative and Causal Pharmacokinetic Model for Factor VIII in Hemophilia A: A Machine Learning Framework for Continuous Model Refinement.
8. PB0824 Prospective Longitudinal Evaluation Shows Increase of VWF and FVIII Activity with Age in Patients with Type 1 and 2 von Willebrand Disease
9. LB 01.1 Efanesoctocog Alfa Prophylaxis for Previously Treated Patients <12 Years of Age with Severe Hemophilia A
10. PB0671 Poor Correlation between Biomarkers and MRI-Detected Joint Damage in a Cross-Sectional Study of Persons with Non-Severe Hemophilia A
11. PB0152 The Spectrum of FVIII-Specific Antibodies in Persons with Hemophilia A: A Cross-Sectional Nationwide Population Study
12. OC 44.3 Exploring Red Blood Cells as a Novel Tolerogenic Approach for Factor VIII Inhibitors Employing Immuno-Dominant FVIII Derived Peptides Presented on MHC Class Ii
13. PB0623 An Enriched Population Pharmacokinetic Model for Recombinant Factor IX-Fc Fusion Including Young Children with Haemophilia B
14. PB0698 Determinants of Desmopressin Response in Bleeding Disorders: a Systematic Review and Meta-Analysis
15. PB0642 Determinants of the Bleeding Phenotype in Persons with Non-Severe Hemophilia
16. Are low-molecular-weight heparins safe and effective in children? A systematic review
17. Clinically relevant differences between assays for von Willebrand factor activity
18. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery
19. Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?
20. Patients’ and health care providers’ perspectives on quality of hemophilia care in the Netherlands: a questionnaire and interview study
21. 5599344 IMPACT OF HOSPITAL ADMISSION FOR VASO-OCCLUSIVE CRISIS ON HEALTH-RELATED QUALITY OF LIFE IN CHILDREN WITH SICKLE CELL DISEASE
22. 5613354 SCREENING FOR CEREBROVASCULAR DISEASE IN CHILDREN WITH SICKLE CELL DISEASE USING TRANSCRANIAL DOPPLER AND MRA TO PREVENT STROKE: THE AMSTERDAM COHORT
23. In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients
24. Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso‐occlusive crisis and steady state
25. Intensity of factor VIII treatment and the development of inhibitors in non‐severe hemophilia A patients: results of the INSIGHT case–control study
26. Mortality caused by intracranial bleeding in non‐severe hemophilia A patients
27. Variation in baseline factor VIII concentration in a retrospective cohort of mild/moderate hemophilia A patients carrying identical F8 mutations
28. Exploring red blood cells as a novel tolerogenic approach for Factor VIII inhibitors employing immuno-dominant FVIII derived peptides presented on MHC class II
29. Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study
30. Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications
31. Inhibitor development and mortality in non‐severe hemophilia A
32. CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease
33. Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease
34. Desmopressin testing in von Willebrand disease: Lowering the burden
35. The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A
36. von Willebrand disease and aging: an evolving phenotype
37. Importance of Genotyping in von Willebrand Disease to Elucidate Pathogenic Mechanisms and Variability in Phenotype
38. Measuring anxiety and depression in young adult men with haemophilia using PROMIS
39. PB2227: HEALTH-RELATED QUALITY OF LIFE OVER TIME IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE ADMITTED FOR VASO-OCCLUSIVE CRISIS.
40. P1502: LONG-TERM FOLLOW-UP OF DUTCH PATIENTS WITH SICKLE CELL DISEASE DIAGNOSED BY NEONATAL SCREENING – EFFECT ON THE MORBIDITY AND MORTALITY IN THE NETHERLANDS.
41. Reduced prevalence of arterial thrombosis in von Willebrand disease
42. The factor VIII treatment history of non-severe hemophilia A
43. Platelet degranulation and bleeding phenotype in a large cohort of Von Willebrand disease patients
44. Outcome measures in European patients with haemophilia: Survey of implementation in routine clinical practice, perception of relevance and recommendations by European treaters in the EHTSB
45. P124: EFFICACY OF NON-PHARMACOLOGICAL INTERVENTIONS TO REDUCE PAIN IN CHILDREN WITH SICKLE CELL DISEASE: A SYSTEMATIC REVIEW
46. S117: LONG-TERM FOLLOW UP OF DUTCH PATIENTS WITH SCD DIAGNOSED BY NEONATAL SCREENING -- EFFECT ON THE MORBIDITY AND MORTALITY IN THE NETHERLANDS.
47. European principles of inhibitor management in patients with haemophilia: implications of new treatment options
48. von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients
49. One piece of the puzzle
50. Social participation is reduced in type 3 Von Willebrand disease patients and in patients with a severe bleeding phenotype
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.